These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37245474)

  • 41. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
    Toledo JB; Zetterberg H; van Harten AC; Glodzik L; Martinez-Lage P; Bocchio-Chiavetto L; Rami L; Hansson O; Sperling R; Engelborghs S; Osorio RS; Vanderstichele H; Vandijck M; Hampel H; Teipl S; Moghekar A; Albert M; Hu WT; Monge Argilés JA; Gorostidi A; Teunissen CE; De Deyn PP; Hyman BT; Molinuevo JL; Frisoni GB; Linazasoro G; de Leon MJ; van der Flier WM; Scheltens P; Blennow K; Shaw LM; Trojanowski JQ;
    Brain; 2015 Sep; 138(Pt 9):2701-15. PubMed ID: 26220940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association Between Obstructive Sleep Apnea, Its Treatment, and Alzheimer's Disease: Systematic Mini-Review.
    Kuo CY; Hsiao HT; Lo IH; Nikolai T
    Front Aging Neurosci; 2020; 12():591737. PubMed ID: 33488381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nocturnal Hypoxia and Sleep Fragmentation May Drive Neurodegenerative Processes: The Compared Effects of Obstructive Sleep Apnea Syndrome and Periodic Limb Movement Disorder on Alzheimer's Disease Biomarkers.
    Fernandes M; Chiaravalloti A; Manfredi N; Placidi F; Nuccetelli M; Izzi F; Camedda R; Bernardini S; Schillaci O; Mercuri NB; Liguori C
    J Alzheimers Dis; 2022; 88(1):127-139. PubMed ID: 35570484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People.
    de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
    J Alzheimers Dis; 2021; 81(3):1295-1309. PubMed ID: 33935098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
    J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia.
    Nägga K; Gottfries J; Blennow K; Marcusson J
    Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.
    Chaudhry A; Houlden H; Rizig M
    J Neurol Sci; 2020 Aug; 415():116886. PubMed ID: 32428759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebrospinal fluid and venous biomarkers of shunt-responsive idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis.
    Thavarajasingam SG; El-Khatib M; Vemulapalli KV; Iradukunda HAS; Laleye J; Russo S; Eichhorn C; Eide PK
    Acta Neurochir (Wien); 2022 Jul; 164(7):1719-1746. PubMed ID: 35230552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.
    Rivero-Santana A; Ferreira D; Perestelo-Pérez L; Westman E; Wahlund LO; Sarría A; Serrano-Aguilar P
    J Alzheimers Dis; 2017; 55(2):625-644. PubMed ID: 27716663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
    Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ
    Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.
    Chen DW; Wang J; Zhang LL; Wang YJ; Gao CY
    J Alzheimers Dis; 2018; 61(2):645-651. PubMed ID: 29278891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Obstructive sleep apnea, cognition and Alzheimer's disease: A systematic review integrating three decades of multidisciplinary research.
    Bubu OM; Andrade AG; Umasabor-Bubu OQ; Hogan MM; Turner AD; de Leon MJ; Ogedegbe G; Ayappa I; Jean-Louis G G; Jackson ML; Varga AW; Osorio RS
    Sleep Med Rev; 2020 Apr; 50():101250. PubMed ID: 31881487
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies.
    Tang W; Huang Q; Wang Y; Wang ZY; Yao YY
    J Neurol Sci; 2014 Oct; 345(1-2):26-36. PubMed ID: 25086857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
    Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
    Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease.
    Degerman Gunnarsson M; Ingelsson M; Blennow K; Basun H; Lannfelt L; Kilander L
    Alzheimers Res Ther; 2016 Jun; 8(1):22. PubMed ID: 27263933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.